BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33660512)

  • 1. Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors.
    Trotta AM; Aurilio M; D'Alterio C; Ieranò C; Di Martino D; Barbieri A; Luciano A; Gaballo P; Santagata S; Portella L; Tomassi S; Marinelli L; Sementa D; Novellino E; Lastoria S; Scala S; Schottelius M; Di Maro S
    J Med Chem; 2021 Mar; 64(6):3449-3461. PubMed ID: 33660512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
    Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
    Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
    Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
    Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
    Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
    Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
    Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A radiogallium-DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging.
    Sano K; Masuda R; Hisada H; Oishi S; Shimokawa K; Ono M; Fujii N; Saji H; Mukai T
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1386-8. PubMed ID: 24491461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
    Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
    Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
    Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
    Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of MMP2 activity in malignant tumors with a 68Ga-labeled gelatinase inhibitor cyclic peptide.
    Liu Q; Pan D; Cheng C; Zhang A; Ma C; Wang L; Zhang D; Liu H; Jiang H; Wang T; Xu Y; Yang R; Chen F; Yang M; Zuo C
    Nucl Med Biol; 2015 Dec; 42(12):939-44. PubMed ID: 26344861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
    Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
    Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4.
    Suzuki K; Ui T; Nagano A; Hino A; Arano Y
    Sci Rep; 2019 Oct; 9(1):15284. PubMed ID: 31653903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
    Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
    Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
    J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
    Brand C; Longo VA; Groaning M; Weber WA; Reiner T
    Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
    Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
    Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Biological Evaluation of
    Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
    Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of
    Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
    Cancer Biother Radiopharm; 2018 Feb; 33(1):8-16. PubMed ID: 29373046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Contrast CXCR4-Targeted
    Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
    Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy.
    Luyten K; Van Loy T; Cawthorne C; Deroose CM; Schols D; Bormans G; Cleeren F
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683912
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Chen CJ; Chan CH; Lin KL; Chen JH; Tseng CH; Wang PY; Chien CY; Yu HM; Lin WJ
    Nucl Med Biol; 2019; 68-69():22-30. PubMed ID: 30578136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.